streptomycin

Streptomycin sulfate (Phytomycin) 是一种能抑制蛋白质合成的氨基糖苷类抗生素。

Kanamycin sulfate (Kanamycin monosulfate) 属于氨基糖苷类抗生素，通过与细菌 70S 核糖体亚基结合来干扰蛋白质合成。Kanamycin sulfate 具有抗菌活性，对革兰氏阳性菌和阴性菌及支原体都有抑制作用。

Streptomycin (Agrept) 是一种可从链霉菌中分离得到的氨基糖苷类抗生素，是神经元和心肌细胞中拉伸激活和机械敏感离子通道的阻滞剂，具有抗结核活性，可与核酸强结合，干扰和阻断蛋白质合成，可用于研究结核杆菌感染。

Hydroxystreptomycin is a new antibiotic isolated from Streptomyces Griseocarneus.

Streptomycin-BSA是Streptomycin与牛血清白蛋白(BSA)缀合的半抗原-载体蛋白偶联物。Streptomycin属于半抗原，单独存在时不能诱导免疫应答，需要偶联大分子蛋白质成为完全抗原才具有免疫原性。

Streptomycin-KLH是Streptomycin与血蓝蛋白(KLH)缀合的半抗原-载体蛋白偶联物。Streptomycin属于半抗原，单独存在时不能诱导免疫应答，需要偶联大分子蛋白质成为完全抗原才具有免疫原性。

Streptomycin-OVA是Streptomycin与鸡卵白蛋白(OVA)缀合的半抗原-载体蛋白偶联物。Streptomycin属于半抗原，单独存在时不能诱导免疫应答，需要偶联大分子蛋白质成为完全抗原才具有免疫原性。

Dihydrostreptomycin is an antibiotic.

Dihydrostreptomycin sulfate (Dihydrostreptomycin sesquisulfate) 是一种氨基糖苷类抗生素，可研究牛、猪和羊的细菌性疾病。

Streptoniazid是一种链霉素的衍生物，是一种对抗结核病有效的抗生素。

Streptomyces A-Factor is a microbial hormone found in Streptomyces griseus. A-factor triggers streptomycin biosynthesis and cell differentiation by binding a repressor-type receptor protein (ArpA) and dissociating it from DNA.

Streptobiosamine is a disaccharide component of streptomycin.

OPC-167832 is a potent and orally active dprE1 Inhibitor with an IC50 of 0.258 μM. OPC-167832 has antituberculosis activity and can be used for the research of tuberculosis caused by Mycobacterium tuberculosis[1]. OPC-167832 exhibits very low MICs against laboratory strains of M. tuberculosis H37Rv (MIC: 0.0005 μg ml) and Kurono (MIC: 0.0005 μg ml) and strains with monoresistance to rifampin (RIF), isoniazid (INH), ethambutol (EMB), streptomycin (STR), and pyrazinamide (PZA) (MIC: 0.00024-0.001 μg ml). However, OPC-167832 has minimal or no activity against standard strains of nonmycobacterial aerobic and anaerobic bacteria[1].The IC90 values of OPC-167832 against intracellular M. tuberculosis strains H37Rv and Kurono are 0.0048 and 0.0027 μg ml, respectively. OPC-167832 shows bactericidal activity against intracellular M. tuberculosis at a low concentration, and the bactericidal activity is saturated at concentrations of 0.004 μg ml or higher[1]. OPC-167832 (oral administration; 0.625-10 mg kg) exhibits a good pharmacokinetic characteristic. The plasma reaches peak at 0.5 h to 1.0 h (tmax) and is eliminated with a half-life (t1 2) of 1.3 h to 2.1 h OPC-167832 distribution in the lungs is approximately 2 times higher than that in plasma, and the Cmax and AUCt of OPC-167832 in plasma and the lungs shows dose dependency[1].OPC-167832 (oral administration; 0.625-10 mg kg; 4 weeks) significantly reduces lung CFU compared to the vehicle group. The dose-dependent decrease of lung CFU is observed from 0.625 mg kg to 2.5 mg kg. In a M. tuberculosis Kurono-infected ICR female mice model. OPC-167832 combines with DMD, BDQ, or LVX via oral gavage exhibits significantly higher efficacies than each single agent alone[1].[1].OPC-167832 (oral gavage; 2.5 mg kg; combination with DCMB; 12 weeks) demonstrates the most potent efficacy when compares with DC, DCB. The lung CFU count after 6 weeks of treatment is below the detection limit, and at the end of just 8 weeks of treatment, the bacteria in the lungs of all the evaluated mice had already been eradicate[1]. [1]. Norimitsu Hariguchi, et al. OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor.Antimicrob Agents Chemother. 2020 May 21;64(6):e02020-19.

Senfolomycin B 对于革兰氏阳性菌和分枝杆菌表现出抗菌活性，并且对耐青霉素、链霉素、新霉素、大环内酯类抗生素的金黄色葡萄球菌也有效。Senfolomycin A 对于革兰氏阴性菌也具有较弱的抗菌作用。

Paulomycin B 显示对抗革兰氏阳性菌的活性，能够抑制抵抗青霉素、链霉素、新霉素以及大环内酯类抗生素的金黄色葡萄球菌。

Paulomycin A2 展现出对革兰氏阳性菌的抗菌活性，能够抑制那些对青霉素、链霉素、新霉素及大环内酯类抗生素产生耐药性的金黄色葡萄球菌。

Paulomycin A (Volonomycin A) 对革兰氏阳性菌具有抗菌作用，能够抑制耐青霉素、链霉素、新霉素及大环内酯类抗生素的金黄色葡萄球菌。

Ashimycin B 是一种与Streptomycin类似的化合物，具有广泛的抗菌活性。

Ashimycin A 是一种与Streptomycin相似的化合物，具备广泛的抗菌性能。

Senfolomycin A 对革兰氏阳性菌和分枝杆菌表现出活性，并对耐青霉素、链霉素、新霉素和大环内酯类抗生素的金黄色葡萄球菌有效，对革兰氏阴性菌的活性较弱。